M Holdings Securities’s Agile Therapeutics AGRX Stock Holding History

M Holdings Securities’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-18	Closed	-$75K	–	502
2021 Q1	$75K	Buy	+18	New	+$97.3K	0.01%	485

Other funds holding AGRX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

M Holdings Securities's AGRX Position: Q2 2021 in Review

M Holdings Securities sold out of Agile Therapeutics (AGRX) in Q2 2021, closing a stake of 18 shares — an estimated $75K sold.

M Holdings Securities first reported a position in AGRX in Q1 2021 and held it in 1 quarter. The position peaked at $75K in Q1 2021. 64 funds tracked by Wall St. Rank hold AGRX as of Q2 2021.

M Holdings Securities reported no remaining Agile Therapeutics position as of Q2 2021 after selling out during the quarter.
M Holdings Securities sold 18 Agile Therapeutics shares in Q2 2021, an estimated $75K.
M Holdings Securities first reported a position in Agile Therapeutics in Q1 2021 and held it in 1 quarter.
M Holdings Securities's Agile Therapeutics position peaked at $75K in Q1 2021.
64 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2021.

Based on M Holdings Securities's 13F filing for Q2 2021, filed 19 Aug 2021.